ROARABLE
Today ⌘ Pro Terminal Big Ideas 🎲 Predictions Screener πŸ¦‹ Butterfly 8 Analysts πŸ›οΈ Policy 🎬 Video β˜… Watchlist 🎲 Prediction Markets πŸ“Š RQD Track Record πŸ“… Next Catalysts πŸ›‘οΈ Overlap & Crash X-Ray πŸ“° Live Wire πŸ‹ 13F Whales πŸ›οΈ Congress & CEO Buys πŸ† $100K Arena ⌘ Pro Terminal πŸ“ Methodology & Corrections
Stock Ratings / Health Care / EXEL / financials
HALO (75) NBIX (73) BNTX (52) TWST (52) ⌘ Pro Terminal β†’

Exelixis Inc. (EXEL) Revenue-to-Profit Sankey Flow & SEC XBRL Financials

$69.39 +4.82% NASDAQ β€’ Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $70.16

Exelixis Inc. (EXEL) earns a Roarable Rating of A (Strong Buy) with 89/100 RQD Confidence. High-quality cash engine (96% profit margin, 35% return on capital) with steady institutional support. The company’s underlying cash engine and institutional positioning keep the composite score in the Green Buy zone.

πŸ“Š Historical Track Record: Scores of 89/100 (A) historically ranked in the Top 4% of excess returns over the next 90 days (+9.7% avg 90D alpha vs SPY β€’ 74.2% hit rate) β†’
ROARABLE A β€’ STRONG BUY Cap $16.40B
πŸ“€ Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚑ INSTANT AI QUANT PREVIEW β€’ $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on EXEL Below β€” or Connect Your Own ChatGPT / Claude
πŸ€– Mara Quenwick β€’ AI Quant Lead (Click for Instant Brief) Is EXEL stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
β–Ό

As of 2026-11-02, Exelixis Inc. (NASDAQ: EXEL) is rated A (Strong Buy / BUY) by Roarable's 5-pillar RQD engine with a composite confidence score of 89/100 at a spot price of $69.39 (+4.82% 1D, market cap $16.40B). Pillar breakdown: Fundamental Cash Engine 20/20, Institutional 13F & Options Flow 18/20, Executive Insider Alignment 18/20, FRED Macro Regime Fit 17/20, and SEC Balance-Sheet Forensics 16/20. Across 1016 tracked Health Care issuers, EXEL ranks #2 in composite RQD confidence.

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– Ellis Vennor β€’ AI Peer & Flow Quant (Click for Instant Brief) How does EXEL compare to HALO and NBIX in the Health Care sector?
β–Ό

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), EXEL carries a Roarable A (89/100 RQD), trailing P/E of 21.0x, gross margin of 96.0%, and ROIC of 35.1%. By comparison, HALO (Halozyme Therapeutics Inc.) holds a B grade (75/100 RQD, P/E 47.0x, ROIC 18.0%, cap $14.89B) and NBIX (Neurocrine Biosciences Inc.) posts a B grade (73/100 RQD, P/E 31.1x, ROIC 15.7%, cap $14.88B). Among the 5-stock peer group, EXEL leads on earnings multiple (21.0x) while EXEL leads on capital efficiency (35.1% ROIC).

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– Gideon Ashmere β€’ AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for EXEL?
β–Ό

Per EXEL's SEC EDGAR XBRL 10-K filing (FY2025, filed 2026-01-02, CIK 0000939767), Exelixis Inc. generated $2.32B in revenue (+7.0% YoY), $782.6M in net income, and $875.8M in free cash flow against $2.84B in total assets and $307.4M in total debt. Key quantitative strengths: Strong cash generator (96% profit margin)β€”profits are backed by real money, not accounting tricks.. Primary risk factors monitored: Broader market pullbacks can still drag down strong stocks in the short run.. Institutional options positioning shows a 50% call / 50% put premium split.

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists β€” not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
πŸ›‘οΈ Portfolio Crash X-Ray
EXT / AFTER-HRS: $70.16 (+1.11%)🧬 Cannibal Buyback (-2.36% YoY Shares)βš™οΈ Cash Engine: 20/20 (A+) β€’ 37.7% FCF Margin
Verify 90D Bucket Audit β†’
πŸ“Š Historical Track Record: Scores of 89/100 (A) historically ranked in the Top 4% of excess returns over the next 90 days (+9.7% avg 90D alpha vs SPY β€’ 74.2% hit rate).
Audit Bucket Track Record β†’
RQD QUANT TACHOMETERSTRONG BUY β€’ A
025507510089
3-of-3 JEV AI Jury Bullish
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) β€” not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw A Β· Rk A
Cash (20)Whales (18)SEC (18)Macro (17)CEO (16)
Each axis scored 0–20
12M PRICE TARGET CONE+14% Base Target
$93 Bull$79 Base$57 Bear
πŸ“¬ FREE EXEL RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: β€” (No Active Options Snapshot on file for EXEL)Realized 20D OHLCV Swing Band: Β±5.4%
Deterministic 5-Pillar Attribution (89/100 Composite)
πŸ” WHY EXEL SCORES 89/100 (A) β€” TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
β–² #1 Bullish Driver: Cash Engine Quality+20/20 pts (22% of score)

SEC XBRL FY 2025 (10-K): 37.7% FCF Margin ($875.8M FCF) & 96.4% Gross Margin

β–² #2 Bullish Driver: Whale & Options Positioning+18/20 pts (20% of score)

20D Institutional Volume Accumulation (Β±5.4% realized swing band)

β–Ό #1 Drag / Risk Factor: Insider Conviction & Share Dilution16/20 pts (-4 pt drag)

Cannibal Buyback (-2.36% YoY Shares) & executive Form 4 sales trim 4 pts from alignment

πŸ“ˆ PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 β†’ Q2 β†’ Q3 β†’ Current
Q1 (-3Q)
81
Grade A-$59.51+8.2% Next Q
Q2 (-2Q)
84
Grade A$64.39+1.5% Next Q
Q3 (-1Q)
86
Grade A$65.35+6.2% Next Q
Current
89
Grade A$69.39+9.7% Hist 90D Ξ±
Trajectory: A- (81) β†’ A (89)Full Audit β†’
βš”οΈ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

βš”οΈ Adversarial Opposing Case: Why the EXEL Bull Thesis Could Fail

Gideon Ashmere Forensic Desk β†’

Even with a 89/100 (A) score, EXEL faces multiple-compression risk if 21.0x trailing P/E re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Broader market pullbacks can still drag down strong stocks in the short run.

⚠️ Forensic Kill-Switch #2

Dilution & Margin Drag: Cannibal Buyback (-2.36% YoY Shares) β€” any gross margin slip below 93.9% triggers an automatic RQD downgrade.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($59.86) or 200D SMA ($51.13) invalidates the momentum regime and cuts Target Base ($79.07) toward Bear Floor ($56.90).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $EXELβ€’ $2.4M Crowd Pool β€’ Kalshi / Polymarket Composite
Contract: β€œEXEL Beats Next Quarter EPS Consensus (Jan 1, 2027) & Holds Above 200D SMA”
YES 89%NO 11%Trade / Inspect Odds β†’
VISUAL REVENUE-TO-PROFIT SANKEY WATERFALL β€’ FY 2025 (10-K)

How EXEL Turns Every Dollar of Sales Into Real Bottom-Line Profit

Free Cash Flow:$875.8M (37.7% FCF Margin)
Revenue$2.32BGross Profit $2.24B (96.4%)Cost of Sales $83.7MOp Profit $872.2M (37.6%)OpEx (R&D/SG&A) $1.36BNet Profit$782.6M (33.7%)Tax/Other $89.6M

Multi-Year SEC EDGAR XBRL Revenue, Net Profit & Free Cash Flow Trajectory

β–  Revenueβ–  Net Profitβ–  Free Cash Flow
FY23
Rev $1.83B
FY24
Rev $2.17B
FY25
Rev $2.32B
Fiscal YearRevenueGross MarginOp MarginNet ProfitFree Cash FlowROIC %
FY 2025$2.32B96.4%37.6%$782.6M$875.8M34.7%
FY 2024$2.17B96.5%27.9%$521.3M$671.5M20.4%
FY 2023$1.83B92%9.3%$207.8M$251.0M2.5%
ON-DEMAND RQD QUANT WORKSHOP β€’ SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring EXEL)

  • βœ“Walkthrough of EXEL's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • βœ“3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • βœ“Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) β†’$100K Arena
EXEL // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +57.10%β–² ASCENDING CHANNEL
2026-11-02O $66.28H $69.39L $66.20C $69.39VOL 2.84M
RES: $72.45SUP: $52.15SMA50: $59.86SMA200: $51.13
$74.23$65.41$56.59$47.76$38.94RES $72.45SUP $52.15$69.392026-05-042026-06-172026-08-042026-09-182026-11-02
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

EXEL Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

πŸ¦‹ EXEL Butterfly Map β†’ + Track EXEL β†’
Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)
14.6%/yr Implied 5Y Growth

vs. +7.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on EXEL today. View full Setup Ledger β†’

πŸ¦‹ Documented & Second-Order Butterfly Connections Open Graph β†’

No direct multi-tier Butterfly edges indexed yet for EXEL. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for EXEL today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk β†’
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT β€’ SEC EDGAR XBRL Γ— RQD PEER BENCHMARK

πŸ“Š Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (EXEL)

Health Care Rank #2 of 1016 βš”οΈ HALO vs EXEL Full Matrix β†’

1. Head-to-Head Health Care Peer Comparison (EXEL vs. HALO, NBIX, BNTX, TWST)

Industry: Biotechnology: Biological Products (No Diagnostic Substances) (156 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Exelixis Inc. (EXEL) ranks #2 by composite RQD confidence (89/100, grade A) and #78 by equity capitalization ($16.40B). Within this direct 5-issuer industry benchmark cohort, EXEL leads on earnings valuation at 21.0x trailing P/E, while EXEL leads on capital efficiency and profitability with 35.1% ROIC and 96.0% gross margin. EXEL currently leads its immediate peer cohort in composite quantitative strength at 89/100 (A).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
EXEL ACTIVE
Exelixis Inc.
A 89/100 21.0x 96.0% 35.1% +4.82% $16.40B Benchmark Subject
HALO
Halozyme Therapeutics Inc.
B 75/100 47.0x 83.6% 18.0% -0.21% $14.89B /halo-vs-exel β†’
NBIX
Neurocrine Biosciences Inc.
B 73/100 31.1x 96.0% 15.7% -0.19% $14.88B /nbix-vs-exel β†’
BNTX
BioNTech SE
D+ 52/100 32.8x β€” 9.9% -1.08% $22.39B /bntx-vs-exel β†’
TWST
Twist Bioscience Corporation
D+ 52/100 β€” 94.2% -11.7% -11.92% $11.50B /twst-vs-exel β†’

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K β€’ FILED 2026-01-02 β€’ CIK 0000939767

In its most recent audited fiscal period (FY2025, filed 2026-01-02), Exelixis Inc. (EXEL) reported GAAP revenue of $2.32B (+7.0% vs. FY2024 revenue of $2.17B , and +26.8% cumulative change since FY2023) , GAAP net income of $782.6M, operating cash flow of $884.3M, and free cash flow of $875.8M (+30.4% YoY). On the balance sheet, EXEL closed FY2025 with $2.84B in total assets against $307.4M in total debt (Altman Z-Score: 16.64, Piotroski F-Score: 9/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2026-01-02 $2.32B $782.6M $884.3M $875.8M $2.84B $307.4M
FY2024 (FY) 2025-01-03 $2.17B $521.3M $700.0M $671.5M $2.95B $316.6M
FY2023 (FY) 2023-12-29 $1.83B $207.8M $333.3M $251.0M $9.02B $2.11B

3. EXEL Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

βœ“ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is EXEL stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-02, Exelixis Inc. (NASDAQ: EXEL) is rated A (Strong Buy / BUY) by Roarable's 5-pillar RQD engine with a composite confidence score of 89/100 at a spot price of $69.39 (+4.82% 1D, market cap $16.40B). Pillar breakdown: Fundamental Cash Engine 20/20, Institutional 13F & Options Flow 18/20, Executive Insider Alignment 18/20, FRED Macro Regime Fit 17/20, and SEC Balance-Sheet Forensics 16/20. Across 1016 tracked Health Care issuers, EXEL ranks #2 in composite RQD confidence.

How does EXEL compare to HALO and NBIX in the Health Care sector?

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), EXEL carries a Roarable A (89/100 RQD), trailing P/E of 21.0x, gross margin of 96.0%, and ROIC of 35.1%. By comparison, HALO (Halozyme Therapeutics Inc.) holds a B grade (75/100 RQD, P/E 47.0x, ROIC 18.0%, cap $14.89B) and NBIX (Neurocrine Biosciences Inc.) posts a B grade (73/100 RQD, P/E 31.1x, ROIC 15.7%, cap $14.88B). Among the 5-stock peer group, EXEL leads on earnings multiple (21.0x) while EXEL leads on capital efficiency (35.1% ROIC).

What are the biggest fundamental strengths and SEC risk factors for EXEL?

Per EXEL's SEC EDGAR XBRL 10-K filing (FY2025, filed 2026-01-02, CIK 0000939767), Exelixis Inc. generated $2.32B in revenue (+7.0% YoY), $782.6M in net income, and $875.8M in free cash flow against $2.84B in total assets and $307.4M in total debt. Key quantitative strengths: Strong cash generator (96% profit margin)β€”profits are backed by real money, not accounting tricks.. Primary risk factors monitored: Broader market pullbacks can still drag down strong stocks in the short run.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is EXEL trading relative to its 50-day, 200-day, and 52-week technical levels?

EXEL last traded at $69.39 (+4.82% on volume of 5,072,493 shares), positioning the stock +15.92% above its 50-day simple moving average ($59.86) and +35.71% above its 200-day simple moving average ($51.13). Across its 52-week range of $36.00 to $72.10, EXEL sits at the 92.5% percentile with a 14-day RSI of 63.3 (BULLISH MOMENTUM) and an implied next-earnings move of Β±5.4% ($65.64 to $73.14).

EXEL Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS β€’ SEC EDGAR Γ— CBOE Γ— FRED

How profitable is Exelixis Inc. (EXEL)?

In FY 2025 (10-K), EXEL converted $2.3B of revenue into a 96.4% gross margin, 37.6% operating margin, and $875.8M in free cash flow (37.7% FCF margin).

Direct Sub-Reports: EXEL RQD Cockpit EXEL 12M Forecast EXEL Earnings & Move EXEL Dividends & DRIP EXEL Insiders & 13F EXEL Whale Options EXEL Profit Sankey EXEL News & Why
ROARABLE RATING BRIEF β€’ RQD 89/100 (A) βœ“ STAGE-C NUMBER FIREWALL VERIFIED

EXEL β€” Exelixis Inc.: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5
As of: 2026-11-02T15:14:21Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD rating, EXEL scores 89 out of 100, grading A and carrying the verdict "Roarable Strong Buy β€” Excellent Cash & Whale Support." The five pillars are: Fundamental Cash Engine at 20/20 (ROIC 35.1%; FCF yield 5.34%), Whale 13F Flow at 18/20 (institutional accumulation and options positioning), Insider Conviction at 16/20 (SEC Form 4 and Congressional PTR cluster flow), Macro Regime Fit at 17/20 (Beta 0.96; sector sensitivity), and Forensic Balance Sheet at 18/20 (Altman Z 16.64; Piotroski F 9/9; Debt/Equity 0.13). For a prospective investor, the strongest pillar is the cash engine, which implies that the reported return on invested capital and free-cash-flow yield are the central support for the rating. The insider and whale pillars are strong but below maximum, indicating supportive but not unanimous ownership signals. The macro pillar's beta near 1.0 suggests market-like sensitivity rather than defensive or aggressive behavior. Valuation is the principal tradeoff: per the market data, trailing P/E is 21 and EV/EBITDA is 18.4, so upside depends on sustained earnings growth rather than multiple expansion. This is an analytical reading of the source data, not personalized financial advice.

Snapshot

PriceMarket CapP/E (TTM)Forward P/EEV/EBITDAEPS (TTM)Dividend YieldBeta52-Wk RangeROIC %
66.2$16.4B2119.518.43.160%0.96$36 - $72.135.1%

Business

Exelixis Inc. (EXEL) is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Biological Products (No Diagnostic Substances) industry. Per the company profile, it carries a market capitalization of $16.4B. The source data does not describe its products, customers, or revenue model beyond the reported financial totals.

Financial Trend

PeriodRevenueOperating IncomeNet IncomeEPSFCFCashDebt
FY 2025$2320.1M$872.2M$782.6MN/A$875.8M$482.5M$307.4M
FY 2024$2168.7M$604.6M$521.3MN/A$671.5M$217.4M$316.6M
FY 2023$1830.2M$170.9M$207.8MN/A$251.0MN/A$2111.1M

Per the SEC financials, revenue rose from $1830.2M in FY 2023 to $2320.1M in FY 2025, and net income rose from $207.8M to $782.6M over the same span. Per the market data, gross margin is 96%, operating margin 37.6%, net margin 33.7%, and ROIC 35.1%. The rating's forensic inputs cite an Altman Z-Score of 16.64 and a Piotroski F-Score of 9/9, and per the Roarable RQD rating, Debt/Equity is 0.13. Reported debt fell from $2111.1M in FY 2023 to $307.4M in FY 2025 while cash rose to $482.5M.

Recent Catalysts & News Wire Analysis

  • Market wire (Yellow): "Exelixis (EXEL) Stock May Be Undervalued As Earnings Stay In Focus" (Yahoo Finance).
  • Market wire (Yellow): "Is Exelixis Stock Engineered To Make You Money?" (Trefis).
  • Market wire (Yellow): "Exelixis (NASDAQ:EXEL) Flashes Strong Technicals and Tight Breakout Setup" (ChartMill).
  • Catalyst (Green): "Citizens raises Exelixis stock price target to $65 on ESMO data" (Investing.com).
  • Risk watch (Red): "Forget the FDA Delay: 3 Reasons Exelixis Is Still a Buy" (The Motley Fool). The headline references an FDA delay; the source does not provide further detail on its timing or scope.
  • Catalyst (Green): "Exelixis (EXEL) Stock May Be A Bargain Despite Its 223% Run" (Yahoo Finance).

The butterfly supply-chain graph reports no supply-chain links and no proprietary signals.

Open Questions

  • What are the company's specific products, and what is the FDA delay referenced in the risk-watch headline?
  • What were reported EPS figures for FY 2023–FY 2025, which the financials list as N/A?
  • What is the cash balance for FY 2023, which is listed as N/A?
  • What analyst consensus rating and price targets exist beyond the single ESMO-related target cited in the news wire?
  • Which institutional, insider, and congressional holders underpin the whale and insider pillar scores?

EXEL Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Exelixis Inc. (EXEL) β€’ Click "Debate This Headline" to argue it in the Roar Pit below

πŸ’¬ Jump to EXEL Debate Forum (3) ↓
πŸ”₯ THE ROAR PIT β€’ LIVE COMMUNITY DEBATE 3 Active Posts & Replies

EXEL Bull vs. Bear Conversation Board β€” What's Your Call at $69.39?

πŸ‚ 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON EXEL 🐻 33% BEARISH CONVICTION
1. Pick Your Side on EXEL:
πŸ’‘ Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
RO RoarDesk_Moderator Roarable Research Desk πŸ‚ BULLISH 🎯 Target: $78.12 (+18.0%)
πŸ“Œ Pinned Debate

πŸ”₯ Official Bull vs. Bear Debate: Is EXEL (A β€’ RQD 89/100) a Buy at $66.20?

Welcome to the EXEL (Exelixis Inc.) Roar Pit. Current RQD Composite is 89/100 (Roarable Strong Buy β€” Excellent Cash & Whale Support) in Biotechnology: Biological Products (No Diagnostic Substances). Bulls point to capital efficiency (35.1% ROIC), while bears focus on macro rate sensitivity and margin execution. Pick your side (πŸ‚ Bull or 🐻 Bear) and drop your price target below.

RI RiskArb_Desk Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $50.31 (-24.0%)
Spot @ $66.20

Pump the brakes on EXEL β€” check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on EXEL, but look at what you are paying: 21.0x trailing P/E with 96.0% gross margins. Unless Exelixis Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

MA MacroHawk_NYC Verified K Arena Trader πŸ‚ BULLISH 🎯 Target: $84.07 (+27.0%)
Spot @ $66.20

EXEL cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on EXEL, the market is fixating on short-term headline noise in Biotechnology: Biological Products (No Diagnostic Substances) and ignoring the balance sheet and cash flow trajectory. At $66.20 (52-wk range $36.00 - $72.10), any beat on forward guidance forces shorts and underweight funds to chase.

LIVE TAPE SPY $755.72 -0.38% QQQ $690.49 -1.44% DIA $517.13 -0.37% IWM $279.33 +0.96% NVDA $204.64 -4.22% AAPL $344.63 -1.23% MSFT $521.91 -1.55% TSLA $399.81 -0.86% PLTR $184.11 -6.27% SOFI $16.76 -4.83% IBIT $43.36 -0.94% GLD $355.78 -1.34%